Valuation check: SPHRY's profit margin is -97.51%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest profit margin for SPHRY is -97.51% as of June 2026. That compares with -200.58% in the prior-year period — up 51.4% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Starpharma Holdings Limited's historical trend and sector peers before judging valuation or financial health.
Over the past year, SPHRY's profit margin moved from -200.58% to -97.51% — a 51.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Starpharma Holdings Limited's valuation or profitability profile.
Against Healthcare companies, SPHRY currently prints -97.51% for profit margin, while the sector average sits near 17.63%. That is roughly 653.2% below the sector mean. Large gaps often invite a closer look at Starpharma Holdings Limited's growth, margins, and balance sheet.
Profit Margin shows how effectively Starpharma Holdings Limited converts resources into returns. At -97.51%, SPHRY may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -200.58% in the prior-year period — up 51.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SPHRY's profit margin (-97.51%), review year-over-year change from -200.58%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.